Abstract PS5-12-18: OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Dana-Farber Cancer Institute, Vita-Salute San Raffaele University, University of Colorado Anschutz, Hospital Universitario 12 De Octubre, Universität Ulm, Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, University of Hong Kong, Institut Gustave Roussy, Fondation Gustave Roussy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129622863